Omalizumab is a first in class humanized monoclonal antibody specific for IgE, approved for the treatment of allergic asthma in 2003 and subsequently for the treatment of chronic spontaneous urticaria (CSU) and nasal polyps. This evidence concerns the gene IGHE and allergic asthma.